Newamsterdam Pharma CO NV 8-K filings

NewAmsterdam Pharma will restate its financial statements for 2021 and 2022 due to errors in calculating net loss per ordinary share.

NewAmsterdam Pharma has amended its sales agreement to replace Cowen with TD Cowen as sales agent for a new at-the-market offering of up to $150 million in ordinary shares.

NewAmsterdam Pharma reported positive topline data from its Phase 3 BROOKLYN trial, extended US patent protection, and maintains a strong cash position of $430.7 million.

NewAmsterdam Pharma's Phase 3 BROOKLYN trial demonstrated significant LDL-C reduction with obicetrapib in patients with heterozygous familial hypercholesterolemia.

NewAmsterdam Pharma has appointed Wouter Joustra and Mark C. McKenna to its board of directors, following the resignation of Sander Slootweg.

NewAmsterdam Pharma has been granted a new composition of matter patent for obicetrapib, extending its intellectual property protection until July 2043.

NewAmsterdam Pharma held its 2024 annual general meeting, where shareholders approved the annual accounts, director appointments, and auditor selections.

NewAmsterdam Pharma reported significant progress in its clinical trials, including the completion of enrollment in the PREVAIL cardiovascular outcomes trial, and provided its first quarter 2024 financial results.

NewAmsterdam Pharma has appointed Juliette Audet as Chief Business Officer, effective April 1, 2024, coinciding with her resignation from the company's Board of Directors.

NewAmsterdam Pharma released an updated corporate investor presentation on its website on March 4, 2024.

NewAmsterdam Pharma announced its full year 2023 financial results and provided updates on its clinical trials, including timelines for topline data from key Phase 3 studies.

NewAmsterdam Pharma has launched a public offering to raise approximately $175.3 million through the sale of ordinary shares and pre-funded warrants.

NewAmsterdam Pharma has released an updated investor presentation highlighting the progress of its lead drug candidate, obicetrapib, in multiple Phase 3 trials for hypercholesterolemia and its potential in other therapeutic areas.